P
PregLem
Swiss-based specialty biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine
About PregLem
Preglem is a healthcare company specializing in the development of innovative treatments for uterine fibroids and endometriosis, two prevalent benign gynecological conditions affecting women of reproductive age. These conditions often lead to significant physical morbidity and impaired quality of life, making effective treatment crucial. Preglem operates in the reproductive medicine market, focusing on pioneering first-in-class medical treatments that change the rules of treatment and drug performance. The company serves healthcare providers and patients, offering advanced therapeutic solutions that aim to preserve the integrity of womanhood. Preglem's business model involves research and development, followed by commercialization of their treatments through exclusive licensing agreements, such as their partnership with Myovant Sciences to commercialize Relugolix Combination Tablet in specific territories outside the U.S. Revenue is generated through the sale of these specialized treatments and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Geneva, Switzerland
- Employees
- 104
- Open positions
- None listed
- Dealroom signal
- 65.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Innovation Management, Developer Tools, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2010 | $461M | $461M | Gedeon Richter | — |
| SERIES BOther financing | Dec 2007 | $33M | $132M | Sofinnova Partners · MVM Life Science Partners · NeoMed · Sofinnova Investments | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for PregLem is 160 monthly website visits, up 6.7% over the last three months. PregLem's team declined 26.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
NeoMed
Sofinnova Partners
MVM Life Science Partners
Sofinnova Investments
Other known investors1 additional known investor
Gedeon Richter
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PregLem on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PregLem’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.